MANKIND PHARMA LTD Q1 RESULTS
Bino Pathiparampil expects positive momentum in pharma sector; has 3 top picks
Bino Pathiparampil of Elara Capital discussed the strong Q1 FY25 performance in the pharma sector. Companies like Lupin and Dr Reddy's received upgrades, largely due to their success in the US market. Despite high valuations, the sector's positive momentum is likely to persist, with Zydus Lifesciences noted for future product launches.
Glenmark Q1 Results: Net profit doubles to Rs 340 crore
Glenmark Pharma net profit doubled to Rs 340 crore crore in Q1FY25 led by robust sales growth in India and Europe and reduction in finance, depreciation and ammortisation costs.
Q1 results today: IRFC, Vodafone Idea among 528 companies to announce earnings on Monday
As the first quarter earnings season nears its end, 528 companies are set to release their results on Monday. Key reports include IRFC, Vodafone Idea, and NMDC. Vodafone Idea is expected to report flat revenue and losses between Rs 7,489-8,100 crore. EBITDA is forecasted to see a slight year-on-year rise despite challenges.
Q1 results this week: HAL, Ola Electric, Vodafone Idea, IRFC, and Nykaa among 85 companies to announce quarterly earnings
Several widely followed companies, including Vodafone Idea, Hindustan Aeronautics (HAL), Mazagon Dock, Hero MotoCorp, IRFC, IRCTC, HUDCO, Apollo Hospitals, Samvardhana Motherson, GMR Airports Infrastructure, Nykaa, and Ola Electric will be releasing their June quarter report cards this week. Here’s the list:
Aurobindo Pharma Q1 results: Net profit jumps 61% at Rs 919 crore
Revenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker said in a statement.
- Go To Page 1
JB Pharma Q1 Results: Net profit jumps 25% YoY to Rs 177 crore
The drug maker had reported a net profit of Rs 142 crore in the year-ago period.Revenue for the quarter rose 12% YoY to Rs 1004 crore
Alembic Pharma Q1 Results: Net profit rises 12% YoY to Rs 135 crore
Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 14% YoY to Rs 239 crore, while the EBITDA margins contracted 540 basis points on y-o-y basis to 15.3%
AstraZeneca Q1 Results: Net loss reported at Rs 12 cr
Total income stood at Rs 396 crore for the June quarter against Rs 303 crore in the year-ago period, AstraZeneca Pharma India said in a regulatory filing
JB Pharma Q1 Results: Net profit rises 25% YoY to Rs 177 cr
"Our overall performance in the first quarter has been robust. We have reached a new milestone of Rs 1,000 crore in quarterly sales for the first time during any quarter, with improvement across all parameters - revenue, gross profit, operating profit and operating profit margin," CEO and Wholetime Director Nikhil Chopra stated.
Lupin shares surge 6%, hit 52-week high post robust Q1 result
Lupin Share Price: Lupin's shares jumped 6% to a 52-week high after the company announced a 77.2% increase in net profit for the June quarter of FY25. The firm's net profit was Rs 801.3 crore, and revenue rose 16.3% to Rs 5,600.3 crore. Nomura maintained a 'Buy' rating, forecasting continued growth.
Q1 results today: Vedanta among 132 companies to announce earnings on Tuesday
During the first quarter earnings season, 132 companies, including PFC and Tata Power, were scheduled to announce their financial results. Vedanta's net profit was expected to range between Rs 2,197-3,060 crore, with revenue estimates between Rs 35,440-38,674 crore for June 2024. Different brokerages provided varying growth predictions.
Q1 results this week: LIC, Airtel, Vedanta, Eicher Motors, Tata Power and others
Power Finance Corp, Vedanta, Tata Power, Britannia Industries, TVS Motor, Bosch, Shree Cement, Solar Industries, Lupin, Linde India, PB Fintech, PI Industries, Berger Paints, Gujarat Gas, and others will announce their June quarter results.
Divi's Laboratories Q1 Results: Cons PAT jumps 21% YoY to Rs 430 crore, misses estimates
Divi's Laboratories reported a consolidated net profit of Rs 430 crore for the quarter ended June 30, 2024, which was up by 21% over Rs 356 crore reported by the company in the year ago period. It was lower than Street's estimates of Rs 448 crore.
Sun Pharma Q1 Results: Net profit rises 40% YoY to Rs 2,836 crore, beats estimates
Sun Pharma Q1 Results: Sun Pharma reported a 40% increase in consolidated net profit to Rs 2,836 crore, surpassing estimates of Rs 2,638 crore. Revenue rose 6% YoY to Rs 12,653 crore. EBITDA grew 8% YoY to Rs 3,608 crore with margins at 28.5%. India formulation sales reached Rs 4,144 crore, up 16%, constituting 33.1% of total sales.
Mankind Pharma shares drop 2% despite 10% YoY Q1 PAT growth. Buy, sell, or hold?
Mankind Pharma's shares fell 2% to Rs 1,985.50, despite the company announcing a 10% YoY rise in net profit to Rs 543 crore for the first quarter of FY25. Revenues increased 12% YoY to Rs 2,893 crore. Brokerages had mixed reactions, with Macquarie, Motilal Oswal, and Kotak Equities offering varied recommendations.
Q1 results today: ITC, Tata Motors among 88 companies will announce earnings on Thursday
Earnings season commenced with 88 companies announcing results. Key highlights included ITC, Sun Pharma, Tata Motors, Adani Enterprises, and Zomato reporting. ITC and Dabur anticipated revenue growth from cigarettes, hotels, and FMCG segments. Tata Motors projected strong profit growth. Zomato maintained robust performance from prior quarters, offering promising outlooks.
Be a bit cautious in auto stocks and do not chase the particular rally in Maruti: Dipan Mehta
Dipan Mehta of Elixir Equities discussed the outlook for the auto and cement industries, noting potential slowdowns and increased competition. He commented on recent developments in speculative trading regulations, the pharma sector, and the performance of companies like Zomato, Paytm, and Maruti. Mehta advised caution in the auto sector while expressing optimism about select pharma stocks.
Mankind Pharma Q1 Results: Net profit jumps 10% to Rs 543 crore
The drug maker reported net profit of Rs 494 crore in the corresponding period of previous year.Revenue from operations rose 12.2% YoY to Rs 2,893 crore in Q1FY25. On a quarter-on-quarter (QoQ) basis revenue and net profit increased 18.5% and 14%, respectively.
Mankind Pharma Q1 Results: Profit rises 10% YoY to Rs 543 crore
Mankind Pharma Q1 Results: Revenue from operations for the same period increased by 12% year-on-year (YoY) to Rs 2,893 crore, up from Rs 2,579 crore in the previous year. The company reported an EBITDA of Rs 681 crore, reflecting a 4% YoY increase. However, margins for the quarter declined by 188 basis points to 23.54%.
Q1 results today: Maruti, M&M among 115 companies to announce earnings on Wednesday
Q1 results today: In the first quarter earnings season, 115 companies announced results, including Maruti, M&M, Coal India, Adani Power, Tata Steel, Ambuja, and Bank of Baroda. M&M and Maruti expected mixed revenue and profit changes, while Tata Steel's profit was predicted to rise notably amid a revenue drop. Several others also reported their quarterly performance.
Dr. Reddy's Lab Q1 Results: Profit down 1% to Rs 1,392 crore but revenue jumps 14%
Dr. Reddy's Lab Q1 Results: While announcing the quarterly numbers, the company's board also approved split of equity shares in the ratio of 1:5, which means that 1 existing share will split into 5. The company said its revenue growth during the quarter was largely driven by growth in global generics revenues in North America as well as India.
Piramal Pharma Q1 Results: Net loss narrows to Rs 89 crore
Piramal Pharma Q1 Earnings: Piramal Pharma narrowed its net loss to Rs 89 crore in Q1FY25 from a net loss of Rs 99 crore in the corresponding quarter of the previous year.
Cipla Q1 Results: Cons PAT rises 18% YoY to Rs 1,178 crore, beats estimates
Cipla Q1 Results: The profit beat the ET Now Poll estimates of Rs 1,071 crore. Revenue from operations in the reporting period increased 6% year-on-year to Rs 6,694 crore. EBITDA saw a 14% year-on-year increase, reaching Rs 1,716 crore. This growth was primarily driven by the One India business' branded prescription division, which experienced a 10% growth. This growth was particularly strong in focused chronic therapies like respiratory, cardiac, and urology, outpacing the market. The overall chronic mix in the portfolio also improved by 106 basis points year-on-year, reaching 61.5%.
Q1 results today: IndiGo, IndusInd among 69 companies to announce earnings on Friday
Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, ESAF SFB, Equitas SFB, Mangalam Organics, Piramal Pharma, TTK Prestige among others will also declare their results.
Mankind trumps EQT-ADIA to buy BSV for $1.67 bn
This is the largest acquisition by Mankind Pharma, India’s 4th largest pharma company by market share. A formal announcement regarding the deal is likely by this week.
TCS, Infy power D-Street to fresh record highs! Sensex soars 900 points, Nifty tops 24,500 for the first time
Indian markets rose Friday, led by TCS's strong June quarter. Sensex climbed 281 points, Nifty50 up 93 points. Stocks like TCS, Infosys, and Adani Ports surged. Maruti fell. US inflation data raised September Fed rate cut chances, noted by CME FedWatch. RBI's Das predicted 5% retail inflation. Powell's testimony hinted at possible rate cuts.
Q1 Earnings Preview: Flat to 4% growth in net profit expected from Nifty pack; auto, financials, health to outperform
Motilal Oswal and Kotak Mahindra differ in their Q2 earnings projections for the Nifty universe. While Kotak forecasts a nearly flat growth of 0.6%, Motilal Oswal projects a 4% increase in net profits. Both firms predict stronger growth when excluding global commodities. Motilal Oswal anticipates a 10% YoY increase for the Nifty excluding oil & gas and metals, while Kotak forecasts a 9.3% rise excluding oil marketing companies.
Mankind Pharma Q4 Results: Net profit jumps 62% YoY to Rs 477 crore
Mankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation sales and one-off US export opportunities.
Load More
